NCT06092034: An ongoing trial by Rocket Pharmaceuticals Inc.
This trial is ongoing. It must report results 3 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06092034 |
|---|---|
| Title | Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 5, 2023 |
| Completion date | April 30, 2028 |
| Required reporting date | April 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |